Back to Search
Start Over
Access to innovative medicines for metastatic melanoma worldwide
- Source :
- Kandolf Sekulovic, L, Guo, J, Agarwala, S, Hauschild, A, McArthur, G, Cinat, G, Wainstein, A, Caglevic, C, Lorigan, P, Gogas, H, Alvarez, M, Duncombe, R, Lebbe, C, Peris, K, Rutkowski, P, Stratigos, A, Forsea, A M, De La Cruz Merino, L, Kukushkina, M, Dummer, R, Hoeller, C, Gorry, C, Bastholt, L, Herceg, D, Neyns, B, Vieira, R, Arenberger, P, Bylaite-Bucinskiene, M, Babovic, N, Banjin, M, Putnik, K, Todorovic, V, Kirov, K, Ocvirk, J, Zhukavets, A, Ymeri, A, Stojkovski, I & Garbe, C 2018, ' Access to innovative medicines for metastatic melanoma worldwide : Melanoma World Society and European Association of Dermato-oncology survey in 34 countries ', European Journal of Cancer, vol. 104, pp. 201-209 . https://doi.org/10.1016/j.ejca.2018.09.013
- Publication Year :
- 2018
- Publisher :
- Elsevier Limited, 2018.
-
Abstract
- According to data from recent studies from Europe, a large percentage of patients have restricted access to innovative medicines for metastatic melanoma. Melanoma World Society and European Association of Dermato-oncology conducted a Web-based survey on access to first-line recommended treatments for metastatic melanoma by current guidelines (National Comprehensive Center Network, European Society for Medical Oncology [ESMO] and European Organization for Research and Treatment of Cancer/European Association of Dermato-oncology/European dermatology Forum) among melanoma experts from 27 European countries, USA, China, Australia, Argentina, Brazil, Chile and Mexico from September 1st, 2017 to July 1st, 2018. Data on licencing and reimbursement of medicines and the number of patient treated were correlated with the data on health expenditure per capita (HEPC), Mackenbach score of health policy performance, health technology assessment (HTA), ASCO and ESMO Magnitude of clinical benefit scale (ESMO MCBS) scores of clinical benefit and market price of medicines. Regression analysis for evaluation of correlation between the parameters was carried out using SPSS software. The estimated number of patients without access in surveyed countries was 13768. The recommended BRAFi+MEKi combination and anti-PD1 immunotherapy were fully reimbursed/covered in 19 of 34 (55.8%) and 17 of 34 (50%) countries, and combination anti-CTLA4+anti-PD1 in was fully covered in 6 of 34 (17.6%) countries. Median delay in reimbursement was 991 days, and it was in significant correlation with ESMO MCBS (p=0.02), median market price (p=0.001), HEPC and Mackenbach scores (p&nbsp
- Subjects :
- Oncology
Compassionate Use Trials
Cancer Research
Market access
Innovative medicines
Russia
Targeted therapy
0302 clinical medicine
access
Surveys and Questionnaires
Market price
Per capita
METASTATIC MELANOMA
030212 general & internal medicine
Melanoma
Reimbursement
health care economics and organizations
Clinical Trials as Topic
Access
Immunooncology
Metastatic melanoma
Treatment
Health technology
targeted therapy
Europe
Value-Based Purchasing
030220 oncology & carcinogenesis
Scale (social sciences)
Practice Guidelines as Topic
oncology
Guideline Adherence
Settore MED/35 - MALATTIE CUTANEE E VENEREE
medicine.medical_specialty
Gross Domestic Product
Human Development
Drug Costs
Reimbursement Mechanisms
03 medical and health sciences
Internal medicine
medicine
Humans
Health policy
business.industry
Health Priorities
Prescription Fees
Drugs, Investigational
medicine.disease
Latin America
Socioeconomic Factors
business
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Kandolf Sekulovic, L, Guo, J, Agarwala, S, Hauschild, A, McArthur, G, Cinat, G, Wainstein, A, Caglevic, C, Lorigan, P, Gogas, H, Alvarez, M, Duncombe, R, Lebbe, C, Peris, K, Rutkowski, P, Stratigos, A, Forsea, A M, De La Cruz Merino, L, Kukushkina, M, Dummer, R, Hoeller, C, Gorry, C, Bastholt, L, Herceg, D, Neyns, B, Vieira, R, Arenberger, P, Bylaite-Bucinskiene, M, Babovic, N, Banjin, M, Putnik, K, Todorovic, V, Kirov, K, Ocvirk, J, Zhukavets, A, Ymeri, A, Stojkovski, I & Garbe, C 2018, ' Access to innovative medicines for metastatic melanoma worldwide : Melanoma World Society and European Association of Dermato-oncology survey in 34 countries ', European Journal of Cancer, vol. 104, pp. 201-209 . https://doi.org/10.1016/j.ejca.2018.09.013
- Accession number :
- edsair.doi.dedup.....3f58b955fc2570105dc2a792abec6e9f